Efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever in patients with acute dengue: A randomised, double blind, placebo-controlled trial
Gathsaurie Neelika Malavige,Chandima Jeewandara,Ananda Wijewickrama,Dumni Gunasinghe,Sameera D. Mahapatuna,Chathurika Gangani,Vimalahan Vimalachandran,Geethal Jayarathna,Yashoda Perera,Chandanie Wanigatunga,Harsha Dissanayake,Shamini Prathapan,Eranga Narangoda,Damayanthi Idampitiya,Laksiri Gomes,Samurdhi Wickramanayake,Pramodth Sahabandu,Graham S. Ogg,Geethal Jayaratne
DOI: https://doi.org/10.1371/journal.pntd.0010123
2022-06-02
PLoS Neglected Tropical Diseases
Abstract:Rupatadine was previously shown to reduce endothelial dysfunction in vitro, reduced vascular leak in dengue mouse models and to reduce the extent of pleural effusions and thrombocytopenia in patients with acute dengue. Therefore, we sought to determine the efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever (DHF) in patients with acute dengue. A phase 2, randomised, double blind, placebo controlled clinical trial was carried out in patients with acute dengue in Sri Lanka in an outpatient setting. Patients with ≤3 days since the onset of illness were either recruited to the treatment arm of oral rupatadine 40mg for 5 days (n = 123) or the placebo arm (n = 126). Clinical and laboratory features were measured daily to assess development of DHF and other complications. 12 (9.7%) patients developed DHF in the treatment arm compared to 22 (17.5%) who were on the placebo although this was not significant (p = 0.09, relative risk 0.68, 95% CI 0.41 to 1.08). Rupatadine also significantly reduced (p = 0.01) the proportion of patients with platelet counts <50,000 cells/mm 3 and significantly reduced (p = 0.04) persisting vomiting, headache and hepatic tenderness (p<0.0001) in patients. However, there was no difference in the duration of illness and in the proportion of individuals who required hospital admission in both treatment arms. Only 2 patients on rupatadine and 3 patients on the placebo developed shock, while bleeding manifestations were seen in 6 patients on rupatadine and 7 patients on the placebo. Rupatadine appeared to be safe and well tolerated and showed a trend towards a reducing proportion of patients with acute dengue who developed DHF. It usefulness when used in combination with other treatment modalities should be explored. International Clinical Trials Registration Platform: SLCTR/2017/024. Rupatadine was previously shown to reduce endothelial dysfunction in vitro, reduced vascular leak in dengue mouse models and to reduce the extent of pleural effusions and thrombocytopenia in a post-hoc analysis, in patients with acute dengue. Therefore, we sought to determine the efficacy of rupatadine in reducing the incidence of dengue haemorrhagic fever (DHF) in patients with acute dengue. A phase 2, randomised, double blind, placebo controlled clinical trial was carried out in patients with acute dengue in Sri Lanka in an outpatient setting. Patients with ≤3 days since the onset of illness were either recruited to the treatment arm of oral rupatadine 40mg for 5 days (n = 123) or the placebo arm (n = 126). We found that patients given rupatadine were less likely to develop DHF than those on the placebo (relative risk 0.68, 95% CI 0.41 to 1.08) although not significant. Rupatadine also significantly reduced (p = 0.01) the proportion of patients with platelet counts <50,000 cells/mm 3 and significantly reduced (p = 0.04) persisting vomiting, headache and hepatic tenderness (p<0.0001) in patients. Rupatadine appeared to be safe and well tolerated and showed a trend towards a reduced proportion of patients with acute dengue who developed DHF.
tropical medicine,parasitology